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A Novel Platinum Compound Inhibits Constitutive Stat3
Signaling and Induces Cell Cycle Arrest and Apoptosis of
Malignant Cells*
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Previous studies have established constitutive activation of Stat3
protein as one of themolecular changes required for tumorigenesis.
To develop novel therapeutics for tumors harboring constitutively
active Stat3, compounds from the NCI 2000 diversity set were eval-
uated for inhibition of Stat3DNA-binding activity in vitro. Of these,
a novel platinum (IV) compound, IS3 295, interactedwith Stat3 and
inhibited its binding to specific DNA-response elements. Further
analysis suggested noncompetitive-type kinetics for the inhibition
of Stat3 binding to DNA. In human andmouse tumor cell lines with
constitutively active Stat3, IS3 295 selectively attenuated Stat3 sig-
naling, thereby inducing cell growth arrest at G0/G1 phase and apo-
ptosis.Moreover, in transformedcells, IS3295 repressed expression
of cyclin D1 and bcl-xL, two of the known Stat3-regulated genes that
are overexpressed in malignant cells, suggesting that IS3 295 medi-
ates anti-tumor cell activity in part by blocking Stat3-mediated sub-
version of cell growth and apoptotic signals. Together, our findings
provide evidence for the inhibition of Stat3 activity and biological
functions by IS3 295 through interaction with Stat3 protein. This
study represents a significant advance in small molecule-based
approaches to target Stat3 and suggests potential new applications
for platinum (IV) complexes asmodulators of the Stat3 pathway for
cancer therapy.
Cellular responses to growth factors and cytokines are characterized
by the activation of signal transduction pathways, including the signal
transducer and activator of transcription (STAT)2 family of cytoplasmic
transcription factors (1–4). Activation of STAT proteins is initiated
upon their tyrosine phosphorylation, a key event in the formation of
phosphotyrosine-Src homology 2 domain interactions and the dimer-
ization between two STAT monomers. In turn, dimers of STAT pro-
teins translocate to the nucleus and bind to specific DNA-response
elements, thereby inducing the expression of genes essential for cellular
responses. Normal physiological functions of STAT proteins include
regulation of cell proliferation, differentiation, and development and
apoptosis (reviewed in Refs. 5–10).
In contrast to the tightly regulated normal STAT signaling, constitu-
tive activation of STAT proteins is frequently observed in human
tumors (11, 12) and has been linked to tumor progression. Persistent
activation of one STAT family member, Stat3, is detected in breast
cancer, prostate cancer, and head and neck squamous cell carcinoma as
well as in lymphomas and leukemias (Refs. 13–20; reviewed in Refs.
21–28). In malignant cell lines and tumors that harbor constitutively
active Stat3, studies have also revealed overexpression of Stat3-regu-
lated genes encoding the anti-apoptotic proteins Bcl-xL and Mcl-1, the
cell cycle regulators cyclin D1 and c-Myc, and the angiogenesis factor
vascular endothelial growth factor (VEGF) as well as altered expression
of immune modulatory factors (15, 16, 18, 20, 29–31). These abnormal
gene expression changes contribute to dysregulated cell cycle progres-
sion, survival, and angiogenesis and to repressed host immune functions
(reviewed in Refs. 27 and 28). Thus, inhibition of abnormal Stat3 signal-
ing is sufficient to repress the induction of these genes, resulting in cell
cycle arrest and apoptosis of malignant cells (15, 18, 20, 32), sensitiza-
tion of tumor cells to chemotherapy-induced apoptosis (33), anti-tumor
immune responses (31), and tumor regression (32). Therefore, small
molecule inhibitors of Stat3 have the potential to impact tumors that
harbor constitutively active Stat3 with significant clinical benefits.
Previous studies have implicated signal transduction pathways in the
anti-tumor activity of platinum complexes. Evidence shows that cispla-
tinmightmodulate theMAPK family and the phosphatidylinositol 3-ki-
nase/Akt pathway (34–37). We have also reported previously that a
novel class of platinum complexes inhibit Stat3 signaling and induce
tumor regression (38). Here, we demonstrate that a new platinum (IV)
compound, IS3 295, selected from theNCI diversity set (NSC 295558) is
another novel Stat3 inhibitor. Analyses of in vitroDNA-binding activity
and transcriptional regulation indicated that IS3 295 interacted directly
with Stat3, thereby inhibiting Stat3 binding to a consensus DNA-re-
sponse element and Stat3 transcriptional activity. Inhibition of consti-
tutively active Stat3 in malignant cells by IS3 295 suppressed the induc-
tion of Stat3-regulated genes, including bcl-xL and cyclin D1. Studies in
v-Src-transformed fibroblasts as well as in human andmouse tumor cell
lines that harbor constitutive Stat3 activity revealed G0/G1 cell cycle
arrest and apoptosis following treatment with IS3 295, which correlated
with the inhibition of aberrant Stat3 signaling. Altogether, we provide
evidence for direct inhibition of Stat3 and its biological activity by a
novel platinum (IV) complex. These findings have wide clinical impli-
cations, providing the rationale for further mechanistic studies of these
compounds for potential cancer therapy.
EXPERIMENTAL PROCEDURES
Cells and Reagents—The Src-transformed NIH3T3/v-Src, NIH3T3/
v-Src/pLucTKS3, NIH3T3/v-Src/pRLSRE, and NIH3T3/hEGFR fibro-
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CA55652 from the National Institutes of Health (to R. J.). The costs of publication of
this article were defrayed in part by the payment of page charges. This article must
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2 The abbreviations used are: STAT, signal transducer and activator of transcription;
VEGF, vascular endothelial growth factor; MAPK, mitogen-activated protein kinase;
PBS, phosphate-buffered saline; EMSA, electrophoreticmobility shift assay; hSIE, high
affinity sis-inducible element; TUNEL, terminal deoxynucleotidyltransferase-medi-
ated dUTP nick end labeling; BrdUrd, bromodeoxyuridine.
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blasts and the human breast cancer (MDA-MB-231, MDA-MB-435,
MDA-MB-453, and MDA-MB-468), human prostate cancer (DU145),
human (U266) and mouse (5TGM1) multiple myeloma, mouse mela-
noma (B16), and human pancreatic cancer (Panc1) cell lines have all
been described previously (15, 19, 32, 39–43). Cells were grown in
Dulbecco’s modified Eagle’s medium containing 5% iron-supplemented
bovine calf serum with or without G418 or Zeocin or in RPMI 1640
medium containing 10% heat-inactivated fetal bovine serum. Recombi-
nant human epidermal growth factor and interleukin-6 were obtained
from R&D Systems (Minneapolis, MN).
Plasmids—The Stat3 reporter (pLucTKS3), the Stat3-dependent
VEGF promoter-driven reporter (pGL2-VEGF-Luc), and the Stat3-in-
dependent reporter (pLucSRE), all of which drive the expression of fire-
fly luciferase, as well as the Stat3-independent Renilla luciferase
reporter (pRLSRE) have been described previously (11, 30, 44). The
pLucTKS3 plasmid harbors seven copies of a sequence corresponding
to the Stat3-specific binding site in the promoter of the human C-reac-
tive protein gene (45). The pRLSRE and pLucSRE plasmids each contain
two copies of the serum-response element from the c-fos promoter (11,
46) subcloned into the Renilla (pRL-null) or firefly (pGL2) luciferase
reporter, respectively (Promega Corp., Madison, WI). The plasmid
pNFB-Luc is firefly luciferase and was obtained from Stratagene (La
Jolla, CA). The plasmid pRc/CMV-Stat3-FLAG was a gift from Dr.
James Darnell, Jr. (Rockefeller University).
Cytosolic Extract Preparation and Luciferase Assays—Cytosolic
extract preparation from fibroblasts and luciferase assays were
described previously (11, 44). Briefly, after two washes with phosphate-
buffered saline (PBS) and equilibration for 5 min with 0.5 ml of PBS and
0.5 mM EDTA, cells were scraped off the dishes, and the cell pellet was
obtained by centrifugation at 4500  g for 2 min at 4 °C. Cells were
resuspended in 0.4ml of low salt HEPES buffer (10mMHEPES (pH 7.8),
10 mM KCl, 0.1 mM EGTA, 0.1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, and 1mM dithiothreitol) for 15min; lysed by the addition of 20
l of 10%Nonidet P-40; and centrifuged at 10,000 g for 30 s at 4 °C to
obtain the cytosolic supernatant, which was used for luciferase assays
(Promega Corp.) and measured with a luminometer. Cytosolic lysates
were prepared from recombinant baculovirus-infected Sf9 cells for
Stat3 protein as described previously (47). Briefly, cultured dishes of Sf9
cells were washed twice with ice-cold 1 PBS and then PBS containing
1 mM sodium orthovanadate. Cells were lysed in 1% Nonidet P-40 lysis
buffer (50 mMHEPES (pH 7.9), 150 mMNaCl, 1% Nonidet P-40, 20 mM
NaF, 1 mM sodium orthovanadate, 1 mM tetrasodium pyrophosphate, 1
mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM EGTA,
2 mM EDTA, 0.1 M aprotinin, 1 M leupeptin, and 1 M antipain) on
ice for 10min and centrifuged at 13,000 g for 30 s at 4 °C to obtain the
lysate.
Nuclear Extract Preparation and Gel Shift Assays—Nuclear extract
preparation from NIH3T3 fibroblasts stimulated by recombinant
human interleukin-6,NIH3T3/hEGFR fibroblasts stimulated by recom-
binant human epidermal growth factor, v-Src-transformed NIH3T3/v-
Src fibroblasts, and tumor cell lines and electrophoretic mobility shift
assay (EMSA) were carried out as described previously (11, 13, 40). The
32P-labeled oligonucleotide probes usedwere the high affinity sis-induc-
ible element (hSIE) from the c-fos gene (m67 variant, 5-AGCTTCATT-
TCCCGTAAATCCCTA) for Stat1 and Stat3 binding (13, 48) and the
mammary gland factor element from the bovine -casein gene pro-
moter (5-AGATTTCTAGGAATTCAA) for Stat1 and Stat5 binding
(49, 50). Except where indicated, inhibitor compoundwas preincubated
with the nuclear extract for 30 min at room temperature prior to incu-
bation with the radiolabeled probe.
Western Blotting—Whole cell lysates were prepared in boiling SDS
sample loading buffer to extract total proteins from the cytoplasm and
nucleus. Equivalent amounts of total cellular proteinwere electrophore-
sed on an SDS-10% polyacrylamide gel and transferred onto nitrocellu-
lose membranes. Probing of nitrocellulose membranes with primary
antibodies and detection of horseradish peroxidase-conjugated second-
ary antibodies by enhanced chemiluminescence (Amersham Bio-
sciences) were performed as described previously (19, 38, 47). The
probes used were anti-cyclin D1 (Cell Signaling Technologies, Beverly,
MA), anti-Bcl-xL (Cell Signaling Technologies), and anti--actin
(Sigma) antibodies.
Soft Agar Colony Formation Assays—Colony formation assays were
carried out in 6-well dishes as described previously (44). In brief, each
well contained 1.5 ml of 1% agarose in Dulbecco’s modified Eagle’s
medium as the bottom layer and 1.5 ml of 0.5% agarose in Dulbecco’s
modified Eagle’s medium containing 4000 or 6000 NIH3T3/v-Src or
NIH3T3/v-Ras fibroblasts, respectively, as the top layer. Treatment
with IS3 295 was initiated 1 day after seeding cells by adding of 75–100
l of mediumwith or without compound andwas repeated every 3 days
until large colonies were evident. Colonies were quantified by staining
with 20l of 1mg/ml iodonitrotetrazolium violet, incubating overnight
at 37 °C, and counting the next day.
Cell Proliferation and Terminal Deoxynucleotidyltransferase-medi-
ated dUTPNick End Labeling (TUNEL)Assays—Proliferating cells were
first treated with or without IS3 295 for up to 48 h. A portion of the cells
were harvested for bromodeoxyuridine (BrdUrd) (Pharmingen) incor-
poration following themanufacturer’s instructions and analyzed by flow
cytometry. Harvested cells were also analyzed for apoptosis via detec-
tion by TUNEL assay using a Roche Applied Science apoptosis detec-
tion system (fluorescein) according to the manufacturer’s instructions.
Oligonucleotide and Plasmid Transfections—The Stat3 antisense (5-
GCTCCAGCATCTGCTGCTTC-3) and control mismatch (5-
GCTCCAATACCCGTTGCTTC-3) oligonucleotides were synthe-
sized using phosphorothioate chemistry with 2-O-methoxyethyl
modification of the five terminal nucleotides (underlined) (42, 51) to
increase stability. Transfections of antisense Stat3 and plasmids were
carried out using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Briefly, cells were seeded at 1–2  106/
10-cm tissue culture plate 18 h before transfection. Immediately before
transfection, cells were washed once with PBS. Cells were transfected
with luciferase reporters (4 g) in the presence or absence of v-Src (4
g) or transfected with Stat3 (4 g) or pRc/CMV-Stat3-FLAG (4 g).
Antisense Stat3 transfections were carried out Lipofectamine 2000
alone or with Stat3 antisense or mismatch oligonucleotides (final oligo-
nucleotide concentration of 250 nM). After 2–3 h, the transfection
medium was aspirated, and cells were washed with PBS before fresh
medium containing 10% fetal bovine serum was added. Forty-eight h
after transfection, cells were washed, and cytosolic lysates were pre-
pared for luciferase assay as described previously (11, 44) or processed
for TUNEL staining.
Immunohistochemistry—The indirect peroxidase/anti-peroxidase
test was performed on cytospins prepared from cell lines (control and
treated). After inhibition of endogenous peroxidasewith 0.3%H2O2 and
methanol for 30 min, slides were rinsed in PBS (pH 7.4), treated for 30
min with 1.5% normal goat serum, and then incubated for 1 h with
primary antibody against Ki67 (Vector Laboratories, Burlingame, CA)
at 1:100 dilution. Slides were rinsed in PBS and incubated for 30 min
with biotinylated secondary antibody (Vector Laboratories) at 1:200
dilution. Following washing with PBS, the preparations were further
incubated in peroxidase-conjugated avidin (Vector Laboratories). Visu-
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alization was carried out with 3,3-diaminobenzidine (Vector Labora-
tories) for 2 min. For microscopic evaluation, the preparations were
counterstained with hematoxylin andmounted. Negative controls con-
sisted of replacement of the primary antibodywith PBS. The presence of
Ki67 nuclear staining was calculated as the percentage of positive tumor
cells in relation to the total number of cells.
RESULTS
Identification of IS3 295 as an Inhibitor of Stat3 DNA-binding Activity—
Compounds fromtheNCI2000diversity setwere screened for inhibitionof
Stat3 signaling in an in vitroDNA-binding activity assay based on analysis
by EMSA. A platinum (IV) complex, IS3 295 (NSC 295558) (Fig. 1E), was
identified as a potent inhibitor of Stat3 andwas further characterized for its
anti-Stat3 properties. In the in vitroDNA-binding assay, nuclear extracts of
equal total protein containing activated Stat1, Stat3, and Stat5 were prein-
cubated with different concentrations of IS3 295 for 30 min prior to incu-
bation with a 32P-labeled oligonucleotide, the m67 hSIE probe that binds
Stat1 and Stat3, or themammary gland factor element that binds Stat1 and
Stat5. Samples were then subjected to EMSA. The results show that the
presence of IS3 295 in the nuclear extracts led to a dose-dependent reduc-
tion in the levels of theDNA-binding activity of theStat3/Stat3homodimer
(Fig. 1A, panel i, upper band), Stat1/Stat3 heterodimer (panel i, middle
band), and, to a lesser extent, the Stat1/Stat1 homodimer (panels i and ii,
lower bands). In contrast, EMSA analysis showed that the presence of IS3
295 did not significantly affect the level of the DNA-binding activity of the
Stat5/Stat5 dimer (Fig. 1A,panel ii,upper band). These results indicate that
IS3 295 selectively disrupted Stat3 over Stat1 (IC50  1.4 and 4.1 M,
respectively) (Fig. 1A, panel iii), consistent with our previous findings with
other platinum(IV) complexes (38).
In control studies, we evaluated the effect of IS3 295 on the DNA-
binding activity of the E2F1 protein, which is unrelated to STAT pro-
teins. Analysis by EMSA showed that preincubation with IS3 295 of cell
lysates containing E2F1 prior to incubation with a 32P-labeled dihydro-
folate reductase promoter sequence as probe had no significant effect
on the DNA-binding activity (Fig. 1B, panel i). In another control study,
we similarly evaluated the effect of cisplatin on the DNA-binding activ-
ities of Stat1, Stat3, and Stat5 (Fig. 1B, panel ii) (data not shown) and
E2F1 (data not shown) in vitro and found no detectable effect. These
findings together suggest that the effect of IS3 295 is selective for Stat3
and that it is not a general phenomenon of all platinum compounds to
inhibit the activities of transcription factors.
Lack of Effect of IS3 295 on STAT Proteins Pre-bound to DNA—To
further characterize the disruption of in vitro Stat3 DNA-binding activ-
ity by IS3 295, the sequence of the addition of reagents during the DNA-
binding assaywas changed to determine how it affects the kinetics of IS3
295-mediated inhibition. Nuclear extracts containing activated Stat3
FIGURE1. Inhibitionof in vitroStat3DNA-bindingactivitybyaplatinumcomplex.Nuclear extracts or cell lysates containing activated Stat1, Stat3, or Stat5 or E2F1prepared from
NIH3T3/hEGFR fibroblasts stimulatedwith epidermal growth factor or fromSf9 insect cells infectedwith baculovirus expressing Stat1, Stat3, Stat5, or E2F1, respectively, were treated
with orwithout the indicated concentrations of platinumcomplex (IS3 295) or cisplatin for 30min at room temperature prior to incubationwith radiolabeled oligonucleotide probes
and subjected to EMSA analysis. A: panel i, Stat1 and Stat3 binding to the hSIE probe; panel ii, Stat1 and Stat5 binding to the mammary gland factor element probe; panel iii, plot of
the percentage of STAT/STAT-oligonucleotide probe complexes versus the concentration of IS3 295. Inset, IC50 values for the inhibition of STAT/STAT DNA-binding activity. B: panel
i, E2F1binding to thedihydrofolate reductasepromoter oligonucleotideprobe;panel ii, Stat1 andStat3binding to thehSIE probe.C: IS3 295 effect on the in vitroDNA-binding activity
of Stat3 3–30 min after binding (panel i) or in the presence and absence of the inactive Stat3 monomer (panel ii), the inactive Stat1 monomer (panel iii), the inactive Stat5 monomer
(panel iv), or E2F1 protein (panel v). D: Stat1 and Stat3 binding to the IS3 295-treated and untreated (dimethyl sulfoxide (DMSO)) radiolabeled hSIE probe. E: structural formula of IS3
295. The positions of the STAT/STAT-DNA complexes on the gels are labeled. In A–C, the Control lanes represent Me2SO (vehicle) treatment.
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were first incubated with the radiolabeled hSIE probe for 30 min (to
allow prior Stat3 binding to the oligonucleotide probe), followed by the
addition of IS3 295 for an additional 3–30 min, and then subjected to
EMSA analysis. IS3 295 failed to disrupt Stat3 DNA-binding activity
when the protein was first bound to the DNA-response element probe
(Fig. 1C, panel i, compare the first through sixth lanes with the seventh
through twelfth lanes (control)). These findings indicate that DNA-
bound Stat3 protein was occluded from inhibition by IS3 295, suggest-
ing that the Stat3 region required for interaction with IS3 295 is already
bound to DNA. By contrast, EMSA analysis showed that the simultane-
ous addition of IS3 295 and the hSIE oligonucleotide probe to nuclear
extracts containing activated Stat3 protein resulted in inhibition of
Stat3 DNA-binding activity (data not shown), as observed in Fig. 1A,
suggesting that Stat3 has a higher preference for IS3 295 over hSIE.
Interaction of IS3 295 with STAT Proteins—Because the evidence
suggested a possible interaction of activated Stat3 dimers with IS3 295,
we wondered whether inactive STAT monomer proteins could do the
same. To address this, cell lysates of inactive STAT monomer proteins
were added to the cell lysate of activated Stat3, and the mixture was
preincubatedwith IS3 295 for 30min prior to incubationwith the radio-
labeled hSIE probe and EMSA analysis. Although inactive STAT mon-
omer proteins did not bind the DNA-response element or alter the
binding of activated Stat3 dimer protein to DNA (Fig. 1C, panel ii,
seventh lane), if they could interact with IS3 295, we reasoned that they
would lower the concentration of IS3 295 and thereby diminish the
extent of IS3 295-mediated inhibition of the DNA-binding activity of
the activated Stat3 dimer.
Consistent with this possibility, EMSA analysis showed that the pres-
ence of the inactive Stat3 monomer significantly diminished the inhib-
itory effects of IS3 295 on activated Stat3 DNA-binding activity (Fig. 1C,
panel ii, compare the tenth through thirteenth lanes with the second
through fifth lanes). Indeed, the presence of the inactive Stat3monomer
protein completely restored theDNA-binding activity of activated Stat3
dimers that was hitherto abolished by 1–10M IS3 295 (Fig. 1C, panel ii,
eleventh and twelfth lanes versus third and fourth lanes) and resulted in
partial recovery of the activated Stat3 DNA-binding activity that was
otherwise completely disrupted at high concentrations (30 M) of IS3
295 (thirteenth lane versus fifth lane). However, at the level of protein
present in the mixture, the inactive Stat3 monomer was insufficient to
impact higher concentrations (50 M) of IS3 295; and hence, no recov-
ery of activated Stat3DNA-binding activity was observed (Fig. 1C, panel
ii, fourteenth lane). Together, these findings show that the Stat3 mono-
mer interacted with IS3 295 and titrated it out, thereby reducing the
levels that were available to inhibit activated Stat3. The interaction of
IS3 295 with Stat3 protein is independent of the activation status of the
protein.
Similar observations were made when the inactive Stat1 monomer
was present in the mixture (Fig. 1C, panel iii, compare the eighth
through twelfth laneswith the first through sixth lanes), suggesting that
IS3 295 also interacts with Stat1 protein. In contrast, the inactive Stat5
monomer or a non-STAT-related protein, E2F1, failed to significantly
influence the effect of IS3 295 on Stat3 DNA-binding activity (Fig. 1C,
panel iv, compare the eighth through fourteenth lanes with the first
through sixth lanes; and panel v, compare the seventh through twelfth
lanes with the first through sixth lanes).
To investigate the possibility that IS3 295 might alter the integrity of
the hSIE oligonucleotide probe that was used in theDNA-binding activ-
ity studies and thereby inhibit Stat3 binding, the oligonucleotide was
first treatedwith IS3 295 for 30min. The pretreated oligonucleotidewas
then radiolabeled and tested for its ability to bind to activated Stat3 in
vitro. EMSA analysis revealed that the IS3 295-pretreated radiolabeled
hSIE probe bound activated protein similarly to the untreated oligonu-
cleotide probe (Fig. 1D, first lane versus second lane), indicating that the
IS3 295 pretreatment of the oligonucleotide had no observable effect on
the ability of the Stat3-responsive DNA sequence to bind to activated
Stat3 in vitro. Although IS3 295 was in direct contact with the oligonu-
FIGURE 2.Kinetics of IS3 295-mediated inhibition of in vitro Stat3DNA-binding activity.Cell lysates containing activated Stat3were incubatedwith the radiolabeled hSIE probe
for 30 min at room temperature in the presence or absence of IS3 295 and then subjected to EMSA analysis. A, DNA-binding activities for different Stat3 protein amounts in the
presence of increasing concentrations of IS3 295; B, levels of Stat3 binding to increasing amounts of the hSIE oligonucleotide probe in the absence (Control) and presence of IS3 295;
C, levels of Stat3 binding to the hSIE oligonucleotide probe in the presence of increasing concentrations of IS3 295; D, plots of the Stat3/Stat3-hSIE complex versus the levels of hSIE
oligonucleotide probe at different concentrations (0.3–2 M) of IS3 295; E, Lineweaver-Burk analysis (double-reciprocal plot) of the Stat3-hSIE complex versus the levels of hSIE at
different concentrations (0.3–2 M) of IS3 295. The positions of the Stat3/Stat3-DNA complexes on the gels are labeled. DMSO, dimethyl sulfoxide.
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cleotide probe during the pretreatment stage and prior to radiolabeling
of the probe, it is unlikely to have been retainedwith the oligonucleotide
probe following purification of the probe and therefore would not have
come into contact with Stat3 protein at the time of the in vitro DNA-
binding assay. Thus, under the conditions of the in vitro DNA-binding
assay, IS3 295 did not directly alter the binding properties of the Stat3-
responsive DNA element, suggesting that the DNA element may not
directly interact with IS3 295.
Kinetics of IS3 295-mediated Inhibition of Stat3 DNA-binding Activ-
ity—To further explore the interaction of IS3 293with Stat3 protein, the
levels of activated Stat3 protein and the radiolabeled hSIE oligonucleo-
tide probe were varied during the in vitro DNA-binding assay, and the
extent of IS3 295-mediated inhibition was determined. EMSA analysis
showed that in vitro Stat3 DNA-binding activity increased with increas-
ing protein amounts (Fig. 2A, first, sixth, and eleventh lanes). At a low
protein amount (1 g), the presence of IS3 295 caused a strong and
dose-dependent decrease in the level of Stat3 DNA-binding activity
(Fig. 2A, second through fifth lanes), consistent with Fig. 1A (panel i). In
contrast, therewas a diminished effect of IS3 295 on Stat3DNA-binding
activity at higher protein levels (2–3g) (Fig. 2A, sixth through fifteenth
lanes), suggesting that increasing the Stat3 protein amount overcomes
the inhibitory effects of IS3 295 (compare the eighth through tenth and
thirteenth through fifteenth laneswith the third through fifth lanes). The
apparent restoration of Stat3 DNA-binding activity at higher protein
amounts suggests high levels of residual activated Stat3 protein (in
excess of the amount that interacted with IS3 295), which in turn bound
the probe. Altogether, the findings (Figs. 1 and 2A) indicate that IS3 295
interacted with Stat3 protein and thereby inhibited Stat3 DNA-binding
activity.
For the same protein amount, the results further show that increasing
the level of the radiolabeled hSIE probe resulted in an increased level of
in vitro Stat3 DNA-binding activity (Fig. 2,B;C, first, sixth, eleventh, and
sixteenth lanes; and D) until a maximum DNA-binding activity was
reached at higher levels of hSIE (a saturation or plateau phase in the plot
of the Stat3-DNA complex versus the amount of hSIE) (Fig. 2D). In the
presence of IS3 295, however, the maximum binding levels (plateau
phase) attained were diminished, particularly at high concentrations
(1–2M) of IS3 295 (Fig. 2,B–D), suggesting that increasing probe levels
fail to overcome the inhibitory effect of higher concentrations of IS3
295. Instead, varying degrees of saturation of Stat3 DNA-binding activ-
ity were observed with increasing probe levels under high IS3 295 con-
centrations (0.3–2 M) (Fig. 2D). Thus, increasing the oligonucleotide
probe levels did not restore the maximum DNA-binding activity that
was expected for any given amount of protein at different IS3 295 con-
centrations (1 M and higher) (Fig. 2D). A Lineweaver-Burk (double-
reciprocal) plot of the Stat3-DNA complex versus the concentration of
hSIE suggests that the inhibitory effect of IS3 295 on Stat3DNA-binding
activity displays noncompetitive-type kinetics (Fig. 2E), with apparent
changes in affinity and maximum binding levels.
IS3 295 Selectively Blocks Intracellular Stat3 Signaling and Stat3-
mediated Transformation—To further investigate the activities of IS3
295, we treated malignant cells and measured the effects on Stat3 sig-
naling. In stable cell lines harboring constitutively active Stat3
FIGURE 3. Inhibition of Stat3-mediated gene expression by IS3 295. A and B, v-Src-
transformed mouse fibroblasts stably expressing Stat3-dependent (NIH3T3/v-Src/
pLucTKS3) and Stat3-independent (NIH3T3/v-Src/pRLSRE) luciferase reporters or -ga-
lactosidase (-Gal) and normal mouse fibroblasts (NIH3T3) transiently transfected with
pLucTKS3, pGL2-VEGF-Luc, pNFB-Luc, or pLucSRE with or without v-Src were treated
with or without IS3 295 for 48 h. Cytosolic extracts were then prepared from cells for
luciferase and -galactosidase activity measurements. Values are the means  S.D. of
three to five independent assays. C and D, nuclear extracts or whole cell lysates were
prepared from interleukin-6 (IL-6)-stimulated normalmouse fibroblasts (NIH3T3) or their
v-Src-transformed counterparts (NIH3T3/v-Src) and treated with or without IS3 295 for
different times. Samples of equal total proteins were then subjected to in vitro DNA-
binding assay and EMSA analyses or to SDS-PAGE and Western blot analysis for phos-
phorylated and total Stat3 proteins. pY705, phospho-Tyr
705.
FIGURE 4. Abrogation of Stat3-dependent v-Src transformation. v-Src-transformed
fibroblasts (NIH3T3/v-Src) and their Ras-transformed counterparts (NIH3T3/v-Ras) were
seeded on soft agar, and growing cells were treated every 2–3 days with or without the
indicated concentrations of IS3 295 until large colonieswere evident. The number of cell
colonies on soft agar were counted and are expressed as a percentage of the control
(untreated) cells. Values are the means S.D. of three independent assays.
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(NIH3T3/v-Src/pLucTKS3 and NIH3T3/v-Src/pRLSRE) and overex-
pressing Stat3-dependent firefly (pLucTKS3) and Stat3-independent
Renilla (pRLSRE) luciferase reporters (41), IS3 295 strongly suppressed
the induction of the Stat3-dependent reporter but not the Stat3-inde-
pendent luciferase reporter or the induction of -galactosidase in the
v-Src-transformed fibroblasts expressing the -galactosidase vector
(Fig. 3). Similar results were obtained in transient transfection studies of
mouse NIH3T3 fibroblasts with the Stat3 reporter (pLucTKS3) or the
Stat3-dependent VEGF promoter-driven luciferase reporter (pGL2-
VEGF-Luc) (30) following activation of Stat3 by v-Src (11) and treat-
ment with IS3 295 (Fig. 3B, upper two panels). Taken together with the
results in Fig. 1, these findings indicate that IS3 295 blocked the binding
of activated Stat3 to its responsive elements in the promoters of target
genes.Moreover, in a time- and dose-dependentmanner, IS3 295 inhib-
ited the constitutive or ligand-induced activation of Stat3 DNA-binding
activity (Fig. 3C) as well as tyrosine phosphorylation in mouse fibro-
blasts (Fig. 3D) (data not shown). We noted that interleukin-6-induced
Stat3 activation was inhibited by IS3 295 as early as 30 min (Fig. 3C,
lower panel), whereas the inhibition of constitutively active Stat3 in
v-Src-transformedNIH3T3/v-Src fibroblasts by IS3 295 required12 h
to be significant (data not shown). Changes in Stat3 protein levels were
minimum. In contrast, the platinum compound had no inhibitory
effects on the induction of Stat3-independent NFB promoter-driven
(pNFB-Luc) or c-fos promoter-driven (pLucSRE) luciferase reporter
activity in transient transfection studies in mouse fibroblasts (Fig. 3B,
lower two panels). The results show that, at 5–10 M IS3 295, which
inhibited intracellular Stat3 signaling, there was no observable nonspe-
cific effect on the non-Stat3-related pathways investigated here. These
findings together demonstrate that IS3 295 selectively repressed the
tyrosine phosphorylation and DNA-binding activity of Stat3 as well as
the transcriptional regulation in cells by Stat3.
IS3 295 was next evaluated for effects on Stat3-mediated v-Src trans-
formation (11, 12, 44). The results show that treatment of v-Src-trans-
formed NIH3T3/v-Src fibroblasts grown on soft agar with IS3 295
strongly suppressed growth (Fig. 4, left panel). In contrast, similar treat-
ment of v-Ras-transformed NIH3T3/v-Ras fibroblasts grown on soft
agar only partially inhibited growth (Fig. 4, right panel). These findings
are consistent with inhibition of constitutively active Stat3 by IS3 295
and attenuation of growth of v-Src-transformed cells and show that the
IS3 295 inhibitory effect was selective against cells harboring constitu-
tively active Stat3.
IS3 295-induced Block of Cell Cycle Progression and Proliferation—
We further examined the biological effects of IS3 295 and determined
whether any changes might correlate with the inhibition of constitu-
tively active Stat3. Normal NIH3T3 fibroblasts and their v-Src-trans-
formed counterparts (human breast cancer cell lines that harbor con-
stitutively active Stat3 (MDA-MB-435, MDA-MB-231, andMDA-MB-
468) and those that do not (MDA-MB-453 and MCF-7) as well as a
human non-small cell lung cancer cell line (A549), a human prostate
cancer cell line (DU145), and a murine multiple myeloma cell line
(5TGM1) all of which harbor constitutively active Stat3) (19, 42, 52)
were treated with or without IS3 295 for 24 h. Cells were then harvested
for nuclear extract preparation and in vitro Stat3 DNA-binding assay
with EMSA analysis or processed for cell proliferation and cell cycle
analysis by flow cytometry.
EMSA analysis of Stat3 DNA-binding activity in nuclear extracts pre-
pared from malignant cells harboring constitutively active Stat3 and
treated with IS3 295 revealed significant inhibition of constitutive acti-
vation of Stat3 in those cells (Fig. 5A). These observations support the
inhibition of Stat3 transcriptional activity (Fig. 3) and together indicate
that IS3 295 selectively blocked constitutive activation of Stat3 signaling
in diverse cell types. Normal NIH3T3 fibroblasts and the human breast
cancer cell line MDA-MB-453 do not harbor constitutively active Stat3
(Fig. 5A).
Changes in cell proliferation induced by treatment with IS3 295 were
assayed in terms of the Ki67 proliferation index by immunohistochem-
istry. The presence of Ki67 nuclear staining was calculated as the per-
centage of positive tumor cells in relation to the total number of cells. In
contrast to the lack of effect of IS3 295 on the proliferation of normal
NIH3T3 fibroblasts or the human breast cancer cell lineMDA-MB-453
(which does not harbor persistent Stat3 activity), treatmentwith IS3 295
caused significant decreases in Ki67 nuclear staining for the malignant
cells harboring constitutively active Stat3 (Fig. 5B), which correlated
with inhibition of Stat3 activity (Fig. 5A).
FIGURE 5. Evaluation of the effects of IS3 295 on cellular constitutive Stat3 activation and cell proliferation. Normal or malignant cells were treated with or without IS3 295.
Nuclear extracts were prepared for Stat3 DNA-binding activity assay with the hSIE probe, or cells were processed for nuclear Ki67 immunohistochemistry. A, EMSA analysis of Stat3
DNA-binding activity; B, graphical representation of the quantified nuclear staining of the Ki67 proliferation index. The positions of the Stat3/Stat3-DNA complexes on the gels are
labeled. The Ki67 proliferation indexwas calculated as the percentage of positive tumor cells relative to the total number of cells. Ki67 values are representative of three independent
assays. DMSO, dimethyl sulfoxide.
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In flow cytometry analyses for cell cycle changes in IS3 295-treated
and untreated (control) cells exposed to BrdUrd, the results show that
the breast cancer cell line MDA-MB-231 was arrested at G0/G1 phase
following IS3 295 treatment (Fig. 6). A significant decrease in S phase
cells was also observed, which paralleled the drop in DNA synthesis as
judged from the level of incorporation of BrdUrd and persisted for up to
48 h. Similar results were observed after 6 h of IS3 295 treatment of the
breast cancer cell line MDA-MB-468 (Fig. 6) (data not shown). In the
case of the MDA-MB-435 cell line, similar observations were made
following 24 h of treatment (Fig. 6). In contrast, no significant change in
the cell cycle profile was observed when the breast cancer cell line
MDA-MB-453 (which does not harbor constitutively active Stat3) was
treated with IS3 295 (Fig. 6). These findings together show that malig-
nant cells that harbor persistently elevated levels of Stat3 activity were
more sensitive to IS3 295 compared with cells that do not, consistent
with the ability of IS3 295 to inhibit constitutively active Stat3 and its
biological functions.
IS3 295-mediated Apoptosis ofMalignant Cells—Malignant cells that
harbor persistent Stat3 signaling and those that do not were examined
for evidence of apoptosis following treatment with IS3 295. Cells were
analyzed for DNA strand breaks by TUNEL staining. Significant
TUNEL staining was detected in v-Src-transformed NIH3T3/v-Src
fibroblasts; human breast carcinoma cell lines MDA-MB-435, MDA-
MB-468, and MDA-MD-231; human non-small cell lung cancer cell
line A549; human prostate carcinoma cell line DU145; multiple
myeloma cell lines 5TGM1 (mouse) and U266 (human); mouse mela-
noma cell line B16; and human pancreatic cancer cell line Panc1, all of
which harbor constitutively active Stat3, following treatment with IS3
295 (Fig. 7). In contrast, no TUNEL staining was observed in control
(Me2SO-treated) cells or in mouse NIH3T3 fibroblasts and human
FIGURE 6.Analysis of relative cellular DNA content byBrdUrd labeling and flow cytometry. The relativeDNA content of humanbreast cancer cell lines following treatmentwith
or without IS3 295 was analyzed by BrdUrd incorporation and flow cytometry. The population of cells determined from the relative DNA content is shown in each panel for each
treatment condition. The results are representative of three independent determinations. DMSO, dimethyl sulfoxide.
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breast cancer cell line MDA-MB-453 (which do not contain aberrant
Stat3 activity) following treatment with IS3 295 (Fig. 7). The incidence
of apoptosis correlated with the prevalence of constitutively active Stat3
in malignant cells (Fig. 7A, lower panels). Moreover, the incidence of
apoptosis induced by IS3 295 in breast cancer cell lines MDA-MB-468
andMDA-MB-435 (which harbor constitutively active Stat3) compares
favorablywith that induced by other previously investigated Stat3 inhib-
itory approaches, including Stat3 (19), antisense Stat3 (42), and ISS
610 (a peptidomimetic inhibitor of Stat3) (53), and contrasts with the
absence of apoptosis in breast cancer cell line MDA-MB-453 (which
lacks constitutively active Stat3) (Fig. 7B). These results indicate differ-
ences in the sensitivity of cells to IS3 295 that are dependent on the
activation status of Stat3 inside the cells. The susceptiblemalignant cells
are those that harbor constitutively active Stat3; these cells undergo cell
cycle arrest and apoptosis in response to IS3 295, consistent with previ-
ous reports (15, 18–20, 29, 38, 42).
In Vivo Overexpression of Stat3 Protein Affects IS3 295 Activity and
Effect—To further elucidate the interaction between Stat3 and IS3 295,
v-Src-transformed mouse fibroblasts were transfected with Stat3 pro-
tein and then used to investigate IS3 295 activity. The transfection of
wild-type Stat3 into the v-Src-transformed fibroblasts resulted in higher
Stat3 DNA-binding activity compared with the parental fibroblasts as
measured by in vitroDNA-binding activity and EMSA analysis (Fig. 7C,
left panel, third and sixth lanes versus first and second lanes). This was
due to the increased expression of Stat3 protein and the consequent
FIGURE 8. Inhibition of cyclin D1 and Bcl-xL induction by IS3 295. v-Src-transformed
NIH3T3/v-Src fibroblasts and human breast cancer cell line MDA-MB-435 (which con-
tains constitutively active Stat3) were treated with or without the platinum complex for
48 h. Cellswere processed for immunohistochemistry, or cell lysateswere prepared from
cells and subjected to 5% PAGE and Western blot analysis as described under “Experi-
mental Procedures.” A, detection of cyclin D1; B, detection of Bcl-xL. The positions of the
cyclin D1 and Bcl-xL proteins are shown. -Actin levels are shown for normalization of
equal total protein. Data are representative of three independent determinations.
DMSO, dimethyl sulfoxide.
FIGURE7.TUNELanalysis of IS3295-mediatedapoptosis.A, normalNIH3T3 fibroblasts and their v-Src-transformedcounterparts (NIH3T3/v-Src); humanbreast carcinomacell lines
MDA-MB-453, MDA-MB-435, MDA-MB-468, and MDA-MB-231; human non-small cell lung cancer cell line A549; human prostate cancer cell line DU145; multiple myeloma cell lines
5TGM1 (mouse) and U266 (human); mouse melanoma cell line B16; and human pancreatic cancer cell line Panc1 were all treated with or without IS3 295 for 48 h and analyzed by
TUNEL for DNA damage. For each cell line, the activated Stat3 status is indicated:, no constitutively active Stat3;, constitutively active Stat3 (see Fig. 5A). Data are representative
of three independent determinations. B, human breast cancer cell lines MDA-MB-453, MDA-MB-468, and MDA-MB-435 were transfected with or without Stat3 or antisense Stat3
(Stat3AS) or were treated with or without the Stat3 peptidomimetic inhibitor ISS 610 (1 mM) or IS3 295 (5 M). Forty-eight h later, the cells were harvested and processed for TUNEL
analysis. C, v-Src-transformed NIH3T3/v-Src fibroblasts were transfected with or without wild-type Stat3 (pRc/CMV-Stat3-FLAG (Rc/CMV Stat3)) and treated with or without 5 M IS3
295 for 36 h. Cells were subsequently harvested for nuclear extract preparation and Stat3 DNA-binding assay in vitro with EMSA analysis (left panel) or were processed for TUNEL
analysis (right panel). DMSO, dimethyl sulfoxide.
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phosphorylation by oncogenic Src tyrosine kinase present in these cells.
EMSA analysis of nuclear extracts prepared from parental mock-trans-
fected cells and treated with IS3 295 showed significant reduction in
constitutively active Stat3 DNA-binding activity (Fig. 7C, left panel,
fourth and fifth lanes versus first and second lanes), as previously
observed (Figs. 3C, upper panel; and 5A, third and fourth lanes). In
contrast, EMSA analysis showed that cells transfected with exogenous
wild-type Stat3 and treated with IS3 295 showed no significant reduc-
tion in constitutively active Stat3 DNA-binding activity (Fig. 7C, left
panel, sixth lane versus third lane). This finding is consistent with data
from the in vitro DNA-binding assay (Fig. 1C, panel ii) and indicates
that the presence of higher levels of Stat3 protein, either as a monomer
or dimer, diminished the relative potency of IS3 295, thus further con-
firming that IS3 295 interacts with Stat3 protein. Moreover, in dimin-
ishing the effect of IS3 295 on Stat3 DNA-binding activity, the results
show that the overexpression of Stat3 in v-Src-transformed mouse
fibroblastsminimized the extent of IS3 295-mediated apoptosis (Fig. 7C,
right panel, third and fourth images). Finally, this finding is important in
that it suggests that the potency of direct inhibitors of Stat3 activation as
therapeutics for tumors harboring constitutively active Stat3 is influ-
enced by the expression levels of Stat3 protein.
IS3 295 Represses Induction of Bcl-xL and Cyclin D1—To investigate
the molecular changes downstream from Stat3 that may contribute to
the biological responses induced by IS3 295, in situ detection andWest-
ern blot analyses were performed for cell cycle and apoptosis regulators.
The results show that cyclin D1 was significantly diminished in v-Src-
transformedmouseNIH3T3/v-Src fibroblasts and humanbreast cancer
cell line MDA-MB-435 in response to IS3 295-induced inhibition of
Stat3 activation (Fig. 8). Similar observations were made for the anti-
apoptotic protein Bcl-xL in bothmalignant cell lines (which harbor con-
stitutively active Stat3) following treatment with IS3 295 (Fig. 8). These
findings parallel the cell cycle or proliferation changes and the induction
of apoptosis by the IS3 295 treatment (Figs. 5–7) and indicate that inhi-
bition of constitutively active Stat3 by IS3 295 blocked cyclin D1 and
Bcl-xL induction.
DISCUSSION
Signal transduction pathways and transcription factors have taken on
greater significance as molecular targets in cancer drug discovery
because of their central roles in carcinogenesis (27, 28, 54). Previously,
we reported on novel platinum (IV) complexes that inhibit the Stat3
transcription factor and induce anti-tumor cell activity (38). Here, we
present evidence that another novel platinum (IV) complex, IS3 295
(NSC 295558), functions as a Stat3 inhibitor by directly interacting with
the protein. The evidence indicates that IS3 295 interacts with Stat3
protein, both the inactive monomer and the activated dimer, and
represses Stat3 phosphotyrosine levels, DNA-binding activity, and tran-
scriptional regulation. Differences are evident in the modes of activity
and selectivity between IS3 295 and the widely used anti-tumor agent
cisplatin (37, 55), which has no effect on Stat3 activity (38). By contrast,
IS3 295 blocks the binding of activated Stat3 to a specific DNA-response
element. Although the exact site(s) within Stat3 protein that interacts
with IS3 295 is not yet known, preliminary evidence implicates cysteine
residue(s) (data not shown). This is consistent with previous reports
that cisplatin and other platinum complexes interact with cysteine and
methionine residues in serum albumin and -globulins (36, 56–58),
forming thiol conjugates of platinum complexes (57, 59, 60). It is con-
ceivable that such a modification in Stat3 protein by IS3 295 in turn
occludes the binding of Stat3 to its consensus DNA-response element.
A noncompetitive-type inhibition by IS3 295 was observed, sup-
ported by the reduced maximumDNA-binding activity of Stat3 follow-
ing IS3 295 treatment. The treatment of activated Stat3with IS3 295 also
induced an apparent change in the binding affinity of the protein for the
consensus DNA sequence. Inferring from the known interactions of
other platinum complexes with thiol-containing biological molecules
(37, 57, 59, 60), the expected reaction of IS3 295 with thiol groups of
Stat3 would be irreversible. Those previous studies and ours together
suggest that IS3 295 irreversibly modifies Stat3 protein, thereby block-
ing the DNA-binding activity of the protein and subverting its tran-
scriptional and biological functions. The lack of any IS3 295 effect on
Stat3 protein pre-bound to DNA suggests a shielding of the key amino
acid(s) within the protein once the latter is first bound to DNA. This
raises the possibility that both IS3 295 and the consensusDNAsequence
bind to the same region of Stat3 in the DNA-binding domain or that
Stat3 protein undergoes conformational changes upon binding to the
DNA sequence that restrict access to the key amino acid residue(s) and
prevent interaction with IS3 295. Indeed, the crystal structure of the
Stat3 dimer bound to DNA (61) shows that the protein is clamped
around theDNAdouble helix, whichmay be sufficient to impede access
by IS3 295 to the DNA-binding domain.
Previous reports have established constitutively active Stat3 as key to
the dysregulated growth, survival, angiogenesis, and immune evasion
that characterize tumorigenesis (22, 27). The biological effects of IS3
295 aremanifest inmalignant cells harboring constitutively active Stat3,
including inhibition of Stat3-dependent transformation as well as inhi-
bition of cell growth with G0/G1 cell cycle arrest and apoptosis of malig-
nant cells (15, 19, 29, 38). Thus, IS3 295 inhibits Stat3-mediated induc-
tion of critical genes, including the cell cycle regulator cyclin D1, anti-
apoptotic bcl-xL, and pro-angiogenic VEGF, which are important in
tumor processes (15, 30, 62, 63).
In contrast to the DNA denaturation and the formation of platinum-
DNA adducts by cisplatin (37, 64), direct modification of DNA is not a
key factor in the inhibition of Stat3 signaling and biological functions by
IS3 295. Our findings show that the Stat3 binding integrity of the DNA-
response element was preserved following treatment of DNA with IS3
295. Moreover, oligonucleotide melting and re-annealing analysis with
agarose gel electrophoresis showed a retention of the overall integrity of
the IS3 295-treated DNA-response element (data not shown). The
effects of IS3 295 on Stat3 observed here also contrast with those of
cisplatin and others that modulate the phosphatidylinositol 3-kinase/
Akt and MAPK family pathways, which contribute to their biological
effects (34–37). We did not observe any effects of IS3 295 on Stat3-
independent transcriptional events.
In summary, our results provide proof of concept for a novel platinum
compound that interacts with Stat3 and inhibits its biological functions,
suggesting that modulation of Stat3 signaling is an important mecha-
nism of anti-tumor cell activity of platinum (IV) compounds. This study
represents a significant advance in the development of small molecules
that target Stat3 as therapeutics against tumors that harbor constitu-
tively active Stat3 and suggests new applications for platinum (IV) com-
plexes as modulators of Stat3 signal transduction pathways with impor-
tant clinical implications.
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